How I Treat IgA Nephropathy.
作者信息
Reich Heather N, Floege Jürgen
机构信息
Division of Nephrology, University Health Network, Department of Medicine, University of Toronto, Toronto, Ontario, Canada.
Department of Nephrology and Clinical Immunology, Rheinisch Westfälische Technische Hochschule (RWTH) Aachen University Hospital, Aachen, Germany
出版信息
Clin J Am Soc Nephrol. 2022 Aug;17(8):1243-1246. doi: 10.2215/CJN.02710322. Epub 2022 Jun 8.
Abstract
摘要
相似文献
1
How I Treat IgA Nephropathy.我如何治疗IgA肾病。
Clin J Am Soc Nephrol. 2022 Aug;17(8):1243-1246. doi: 10.2215/CJN.02710322. Epub 2022 Jun 8.
2
IgA nephropathy presenting as rapidly progressive glomerulonephritis following first dose of COVID-19 vaccine.接种第一剂新冠疫苗后表现为快速进展性肾小球肾炎的IgA肾病
Pediatr Nephrol. 2022 Feb;37(2):461-462. doi: 10.1007/s00467-021-05351-x. Epub 2021 Nov 16.
3
Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Systematic Review and Meta-Analysis.羟氯喹对 IgA 肾病蛋白尿的影响：系统评价和荟萃分析。
Biomed Res Int. 2021 Dec 3;2021:9171715. doi: 10.1155/2021/9171715. eCollection 2021.
4
IgA nephropathy: an update.IgA肾病：最新进展
Curr Opin Nephrol Hypertens. 2004 Mar;13(2):171-9. doi: 10.1097/00041552-200403000-00005.
5
IgA nephropathy: to treat or not to treat?IgA肾病：治疗还是不治疗？
Nephron. 1997;75(3):251-8. doi: 10.1159/000189545.
6
[Therapy in IgA nephropathy--when and how to do it].[IgA肾病的治疗——时机与方法]
Orv Hetil. 2011 Dec 18;152(51):2039-46. doi: 10.1556/OH.2011.29278.
7
Targeting APRIL in the Treatment of IgA Nephropathy.靶向增殖诱导配体治疗IgA肾病
Clin J Am Soc Nephrol. 2024 Mar 1;19(3):394-398. doi: 10.2215/CJN.0000000000000338. Epub 2023 Oct 6.
8
Selecting Treatment for IgA Nephropathy.IgA肾病的治疗选择
Clin J Am Soc Nephrol. 2023 Sep 1;18(9):1109-1110. doi: 10.2215/CJN.0000000000000263. Epub 2023 Aug 9.
9
Considering the Treatment of IgA Nephropathy.关于IgA肾病的治疗
Clin J Am Soc Nephrol. 2023 Sep 1;18(9):1113-1115. doi: 10.2215/CJN.0000000000000261. Epub 2023 Aug 3.
10
[Concomitant therapy with prednisolone and cyclophosphamide in 18 cases of IgA nephropathy].[18例IgA肾病患者泼尼松龙与环磷酰胺联合治疗]
Nihon Naika Gakkai Zasshi. 1986 May;75(5):611-7. doi: 10.2169/naika.75.611.
引用本文的文献
1
Lifetime progression of IgA nephropathy: a retrospective cohort study with extended long-term follow-up.IgA肾病的终身进展：一项具有长期随访的回顾性队列研究。
BMC Nephrol. 2025 Jan 21;26(1):32. doi: 10.1186/s12882-025-03958-y.
2
Emerging perspectives in the management of IgA nephropathy: a comprehensive review.IgA肾病管理的新观点：全面综述
Porto Biomed J. 2024 Nov 14;9(6):264. doi: 10.1097/j.pbj.0000000000000264. eCollection 2024 Nov-Dec.
3
Use of corticosteroids in Norwegian patients with immunoglobulin a nephropathy progressing to end-stage kidney disease: a retrospective cohort study.挪威免疫球蛋白 A 肾病进展为终末期肾病患者中皮质类固醇的使用：一项回顾性队列研究。
BMC Nephrol. 2024 Jan 29;25(1):42. doi: 10.1186/s12882-024-03481-6.
4
[IgA nephropathy].[IgA肾病]
Urologie. 2024 Jan;63(1):103-111. doi: 10.1007/s00120-023-02268-1.
5
A PRoliferation-Inducing Ligand (APRIL) in the Pathogenesis of Immunoglobulin A Nephropathy: A Review of the Evidence.增殖诱导配体（APRIL）在免疫球蛋白A肾病发病机制中的作用：证据综述
J Clin Med. 2023 Nov 4;12(21):6927. doi: 10.3390/jcm12216927.
6
[IgA nephropathy].[IgA肾病]
Inn Med (Heidelb). 2023 Oct;64(10):961-969. doi: 10.1007/s00108-023-01588-w. Epub 2023 Sep 6.
7
Immune abnormalities in IgA nephropathy.IgA肾病中的免疫异常。
Clin Kidney J. 2023 Feb 8;16(7):1059-1070. doi: 10.1093/ckj/sfad025. eCollection 2023 Jul.
本文引用的文献
1
Executive summary of the KDIGO 2021 Guideline for the Management of Glomerular Diseases.KDIGO 2021肾小球疾病管理指南执行摘要。
Kidney Int. 2021 Oct;100(4):753-779. doi: 10.1016/j.kint.2021.05.015.
2
A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy.预先设定的 DAPA-CKD 试验分析表明，达格列净可改善 IgA 肾病患者的主要不良肾脏事件。
Kidney Int. 2021 Jul;100(1):215-224. doi: 10.1016/j.kint.2021.03.033. Epub 2021 Apr 18.
3
Effect of High-Dose Omega-3 Fatty Acids vs Corn Oil on Major Adverse Cardiovascular Events in Patients at High Cardiovascular Risk: The STRENGTH Randomized Clinical Trial.高剂量ω-3 脂肪酸与玉米油对高心血管风险患者主要不良心血管事件的影响： STRENGTH 随机临床试验。
JAMA. 2020 Dec 8;324(22):2268-2280. doi: 10.1001/jama.2020.22258.
4
Evaluating a New International Risk-Prediction Tool in IgA Nephropathy.评估 IgA 肾病的新型国际风险预测工具。
JAMA Intern Med. 2019 Jul 1;179(7):942-952. doi: 10.1001/jamainternmed.2019.0600.
5
Effects of Hydroxychloroquine on Proteinuria in IgA Nephropathy: A Randomized Controlled Trial.羟氯喹对 IgA 肾病蛋白尿的影响：一项随机对照试验。
Am J Kidney Dis. 2019 Jul;74(1):15-22. doi: 10.1053/j.ajkd.2019.01.026. Epub 2019 Mar 25.
6
Proteinuria Reduction as a Surrogate End Point in Trials of IgA Nephropathy.蛋白尿减少作为 IgA 肾病试验的替代终点。
Clin J Am Soc Nephrol. 2019 Mar 7;14(3):469-481. doi: 10.2215/CJN.08600718. Epub 2019 Jan 11.
7
Effect of Oral Methylprednisolone on Clinical Outcomes in Patients With IgA Nephropathy: The TESTING Randomized Clinical Trial.口服甲泼尼龙对IgA肾病患者临床结局的影响：TESTING随机临床试验
JAMA. 2017 Aug 1;318(5):432-442. doi: 10.1001/jama.2017.9362.
8
Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial.针对 IgA 肾病患者的布地奈德靶向释放与安慰剂的疗效比较（NEFIGAN）：一项双盲、随机、安慰剂对照的 2b 期试验。
Lancet. 2017 May 27;389(10084):2117-2127. doi: 10.1016/S0140-6736(17)30550-0. Epub 2017 Mar 28.
9
Intensive Supportive Care plus Immunosuppression in IgA Nephropathy.IgA 肾病的强化支持治疗加免疫抑制。
N Engl J Med. 2015 Dec 3;373(23):2225-36. doi: 10.1056/NEJMoa1415463.
10
Early increase in blood pressure and diastolic left ventricular malfunction in patients with glomerulonephritis.肾小球肾炎患者早期血压升高及左心室舒张功能障碍
Kidney Int. 1996 Oct;50(4):1321-6. doi: 10.1038/ki.1996.444.
Zotero 插件